Transparency Market Research Projects U.S. Vaccine Market to be Valued at USD 17.4 billion by
U.S. Vaccine Market (Human Vaccines: Hepatitis, Influenza, Meningococcal, Pneumococcal, HPV,
Combination Vaccines; Animal Vaccines: Canine, Feline, Porcine, Bovine, Ovine, Poultry and
Equine) - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
Data from a new report published by Transparency Market Research “U.S. Vaccine Market - U.S.
Industry Analysis, Size, Share, Growth, And Forecast, 2012 - 2018", estimates the U.S. vaccine
market to be worth USD 12.8 billion in 2012 and further expected to reach USD 17.4 billion by
2018, growing at a CAGR of 5.3% from 2012 to 2018.
Browse Full U.S. Vaccine Market Research Report With Complete TOC @
Vaccines for different disorders and illnesses are included among the leading earners in the
pharmaceutical industry. Over the recent years, enhanced research and development in this market
has led to the production of better-quality and effective drugs and vaccines to treat various illnesses.
The vaccine sales in U.S. are growing rapidly at a faster rate as compared to the other prescription
medicines in the market. U.S. has showed a substantial revenue growth in the vaccine production
market increasing the enormity of this industry as well.
The vaccine sales are chiefly resistive to the generic competition that is quoting drug makers
billions of dollars in revenues on each of their top-selling vaccine treatments. Moreover,
government supporting agencies are unfailing buyers of the vaccine products both in the U.S., as
well as across the globe. Hence, U.S. is focused on continuing to lead the global vaccine market
amongst other markets in the world. This drive is also due to the rising prevalence of infectious
diseases in animals and humans, and improvements seen in the biotechnology sector across U.S.